NCT06428903View on ClinicalTrials.gov

Comparative Bioavailability Study of Tablet and Granule Formulations of ADC189 and the Study of Ultra-high Dose

PHASE1CompletedINTERVENTIONAL
Enrollment

48

Participants

Timeline

Start Date

March 12, 2024

Primary Completion Date

September 22, 2024

Study Completion Date

September 22, 2024

Conditions
Healthy Volunteer
Interventions
DRUG

ADC189 tablet

ADC189 tablet, 45 mg, single oral dose in each Group. (Part 1 study)

DRUG

ADC189 granules

ADC189 granules, 45 mg, single oral dose in each Group. (Part 1 study)

DRUG

ADC189 180mg

ADC189 tablet, 180 mg, single oral dose. (Part 2 study)

Trial Locations (1)

250000

Zhao Wei, Jinan

All Listed Sponsors
lead

Jiaxing AnDiCon Biotech Co.,Ltd

INDUSTRY

NCT06428903 - Comparative Bioavailability Study of Tablet and Granule Formulations of ADC189 and the Study of Ultra-high Dose | Biotech Hunter | Biotech Hunter